X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-12 | GNLX | Szalay Aladar | 10% | S - Sale | $2.65 | -64,857 | 3,413,581 | -2% | -$171,678 | |||||
2024-09-11 | GNLX | Tyree James L | Dir | S - Sale | $2.60 | -1,730 | 47,521 | -4% | -$4,499 | ||||||
| M | 2024-09-09 | GNLX | Szalay Aladar | 10% | S - Sale | $2.62 | -75,143 | 3,478,438 | -2% | -$196,609 | |||||
2024-09-03 | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -42,818 | 3,553,581 | -1% | -$89,614 | ||||||
| M | 2024-08-28 | GNLX | Szalay Aladar | 10% | S - Sale | $2.09 | -265,552 | 3,596,399 | -7% | -$554,411 | |||||
| M | 2024-08-23 | GNLX | Szalay Aladar | 10% | S - Sale | $2.19 | -91,630 | 3,861,951 | -2% | -$200,278 | |||||
2024-06-24 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $2.12 | -6,849 | 10,869 | -39% | -$14,520 | ||||||
2024-06-24 | GNLX | Ryder Sean | GC | S - Sale | $2.12 | -5,496 | 19,388 | -22% | -$11,652 | ||||||
2024-06-24 | GNLX | Jewett Caroline | Head of Quality | S - Sale | $2.12 | -4,961 | 16,174 | -23% | -$10,517 | ||||||
| D | 2024-05-29 | GNLX | Tyree James L | Dir | P - Purchase | $0.00 | +6,250 | 9,710 | +181% | +$0 | |||||
| D | 2024-05-29 | GNLX | Smither John W | Dir | P - Purchase | $0.00 | +6,250 | 13,170 | +90% | +$0 | |||||
| D | 2024-05-29 | GNLX | Thomas John | Dir | P - Purchase | $0.00 | +2,500 | 465,960 | +1% | +$0 | |||||
| D | 2024-05-29 | GNLX | Mirabelli Mary | Dir | P - Purchase | $0.00 | +8,000 | 12,460 | +179% | +$0 | |||||
| D | 2024-05-29 | GNLX | Yu Yong | VP, Clinical Trial Operations | P - Purchase | $0.00 | +2,500 | 2,500 | New | +$0 | |||||
| D | 2024-05-29 | GNLX | Zindrick Thomas | Pres, CEO | P - Purchase | $0.00 | +200,000 | 214,651 | >999% | +$0 | |||||
| D | 2024-05-29 | GNLX | Smalling Ralph | Head of Regulatory | P - Purchase | $0.00 | +1,250 | 13,315 | +10% | +$0 | |||||
| D | 2024-05-29 | GNLX | Ryder Sean | GC | P - Purchase | $0.00 | +10,000 | 10,572 | >999% | +$0 | |||||
| D | 2024-05-29 | GNLX | Zak Lourie S. | CFO | P - Purchase | $0.00 | +31,250 | 31,250 | New | +$0 | |||||
| M | 2024-05-13 | GNLX | Szalay Aladar | 10% | S - Sale | $3.63 | -35,966 | 3,953,581 | -1% | -$130,377 | |||||
| M | 2024-05-07 | GNLX | Szalay Aladar | 10% | S - Sale | $3.78 | -19,944 | 3,989,547 | 0% | -$75,300 | |||||
| M | 2024-04-29 | GNLX | Szalay Aladar | 10% | S - Sale | $3.23 | -59,999 | 4,009,491 | -1% | -$193,934 | |||||
| M | 2024-04-22 | GNLX | Szalay Aladar | 10% | S - Sale | $3.51 | -44,395 | 4,069,490 | -1% | -$155,647 | |||||
| M | 2024-04-16 | GNLX | Szalay Aladar | 10% | S - Sale | $3.59 | -71,420 | 4,113,885 | -2% | -$256,227 | |||||
2023-12-15 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $13.16 | -32,535 | 0 | -100% | -$428,180 | ||||||
2023-12-13 | GNLX | Tyree James L | Dir | S - Sale | $13.22 | -9,000 | 3,460 | -72% | -$118,969 | ||||||
2023-12-13 | GNLX | Thomas John | Dir | S - Sale | $13.38 | -9,000 | 463,460 | -2% | -$120,387 | ||||||
2023-12-07 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $11.85 | -36,800 | 32,535 | -53% | -$435,995 | ||||||
2023-11-21 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $10.26 | -18,665 | 69,335 | -21% | -$191,555 | ||||||
2023-10-25 | GNLX | Szalay Aladar | 10% | S - Sale | $19.40 | -5,704 | 4,185,305 | 0% | -$110,638 | ||||||
2023-10-23 | GNLX | Szalay Aladar | 10% | S - Sale | $19.97 | -49,987 | 4,191,009 | -1% | -$998,365 | ||||||
| D | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $19.11 | -5,200 | 106,135 | -5% | -$99,351 | |||||
2023-10-16 | GNLX | Thomas John | Dir | S - Sale | $20.71 | -3,333 | 472,460 | -1% | -$69,038 | ||||||
| D | 2023-10-10 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $22.01 | -5,200 | 106,135 | -5% | -$114,462 | |||||
2023-10-05 | GNLX | Szalay Aladar | 10% | S - Sale | $24.93 | -14,251 | 4,240,996 | 0% | -$355,229 | ||||||
2023-10-03 | GNLX | Szalay Aladar | 10% | S - Sale | $25.49 | -75,690 | 4,255,247 | -2% | -$1,929,225 | ||||||
| M | 2023-09-27 | GNLX | Szalay Aladar | 10% | S - Sale | $24.41 | -13,546 | 4,330,937 | 0% | -$330,669 | |||||
| M | 2023-09-25 | GNLX | Szalay Aladar | 10% | S - Sale | $24.38 | -42,263 | 4,344,483 | -1% | -$1,030,181 | |||||
| D | 2023-09-26 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $23.56 | -5,200 | 106,135 | -5% | -$122,528 | |||||
| M | 2023-09-21 | GNLX | Szalay Aladar | 10% | S - Sale | $27.85 | -16,591 | 4,386,746 | 0% | -$462,001 | |||||
| D | 2023-09-20 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $27.96 | -6,000 | 106,135 | -5% | -$167,786 | |||||
| D | 2023-09-20 | GNLX | Ryder Sean | GC | S - Sale+OE | $30.00 | -10,000 | 572 | -95% | -$300,000 | |||||
| M | 2023-09-18 | GNLX | Szalay Aladar | 10% | S - Sale | $24.92 | -62,459 | 4,403,337 | -1% | -$1,556,591 | |||||
| D | 2023-09-15 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale+OE | $21.89 | -10,400 | 106,135 | -9% | -$227,630 | |||||
| M | 2023-09-15 | GNLX | Thomas John | Dir | S - Sale | $23.45 | -6,667 | 475,793 | -1% | -$156,313 | |||||
2023-09-13 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $21.14 | -29,800 | 106,135 | -22% | -$629,927 | ||||||
| M | 2023-09-13 | GNLX | Szalay Aladar | 10% | S - Sale | $21.80 | -44,308 | 4,465,796 | -1% | -$965,899 | |||||
2023-09-13 | GNLX | Smither John W | Dir | S - Sale | $20.78 | -900 | 6,920 | -12% | -$18,702 | ||||||
| M | 2023-09-11 | GNLX | Szalay Aladar | 10% | S - Sale | $22.23 | -52,616 | 4,510,104 | -1% | -$1,169,868 | |||||
| M | 2023-09-07 | GNLX | Szalay Aladar | 10% | S - Sale | $23.57 | -37,277 | 4,562,720 | -1% | -$878,600 | |||||
2023-08-30 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $24.70 | -19,800 | 135,935 | -13% | -$489,060 | ||||||
2023-08-18 | GNLX | Jewett Caroline | Head of Quality | S - Sale | $23.73 | -515 | 1,135 | -31% | -$12,221 | ||||||
2023-08-18 | GNLX | Smalling Ralph | Head of Regulatory | S - Sale | $23.73 | -935 | 2,065 | -31% | -$22,188 | ||||||
2023-08-18 | GNLX | Samuelson Doug | CFO | S - Sale | $23.73 | -1,297 | 2,303 | -36% | -$30,778 | ||||||
2023-08-18 | GNLX | Ryder Sean | GC | S - Sale | $23.73 | -328 | 572 | -36% | -$7,783 | ||||||
2023-08-18 | GNLX | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $23.73 | -3,265 | 5,735 | -36% | -$77,478 | ||||||
2023-08-18 | GNLX | Yu Yong | VP, Clinical Trial Operations | S - Sale | $23.73 | -3,265 | 155,735 | -2% | -$77,478 | ||||||
2023-08-18 | GNLX | Zindrick Thomas | Pres, CEO | S - Sale | $23.73 | -8,349 | 14,651 | -36% | -$198,122 | ||||||
2023-01-26 | GNLX | Zhang Qian | Associate VP, Research | P - Purchase | $6.25 | +200 | 133,533 | 0% | +$1,250 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |